Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC_News_News & Media Resources_Fosun

Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC

Release time:2023-01-17 Content sourced from： Page View：

share

Previous：COMIRNATY^®Bivalent COVID-19 Vaccine is Officially Approved as Regular Imported Vaccine by the Pharmaceutical Administration Bureau of Macao SAR next：Fosun Receives RMB12 Billion Syndicated Loan from 8 Banks to Jointly Promote Development of the Private Economy

x

抖音二维码

扫一扫